DOCSLIB.ORG

OFFICIAL LIST of SECTION 13(F) SECURITIES USER INFORMATION SHEET

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
OFFICIAL LIST of SECTION 13(F) SECURITIES USER INFORMATION SHEET List of Section 13F Securities Fourth Quarter FY 2014 Copyright (c) 2015 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of December 20, 2014, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending December 31, 2014. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by [ Section 13(f)(1) and Rule 13f-1] thereunder. Features (1) Additions and Deletions: Revisions made to the list of Section 13(f) securities are indicated in a column titled “STATUS.” The word “ADDED” in the status column opposite the name of a security indicates that the security has become a Section 13(f) security. The word “DELETED” in the status column opposite the name of a security indicates that the security ceases to be a 13(f) security since the date of the last list. (2) List of options: An asterisk is placed next to the name of any security having a listed option and each option is individually listed with its own CUSIP number immediately below the name of the security having the option. A manager reporting holdings of options on its Form13F should use the CUSIP number of the underlying securities to which the option relates. CUSIP descriptions and numerical identification date (copyright 1969 through 2015, American Bankers Association) are used with permission. All rights are reserved. Run Date: 1/2/2015 ** List of Section 13F Securities ** Page 1 Run Time: 10:15 Year: 2014 Qtr: 4 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS C15396 AA 9 CANADIAN SOLAR INC DEBT 4.250% 2/1 D18190 89 8 * DEUTSCHE BANK AG NAMEN AKT D18190 90 8 DEUTSCHE BANK AG CALL D18190 95 8 DEUTSCHE BANK AG PUT G00349 10 3 * ABENGOA YIELD PLC ORD SHS G00349 90 3 ABENGOA YIELD PLC CALL G00349 95 3 ABENGOA YIELD PLC PUT G0083B 10 8 * ACTAVIS PLC SHS G0083B 90 8 ACTAVIS PLC CALL G0083B 95 8 ACTAVIS PLC PUT G0129K 10 4 * AIRCASTLE LTD COM G0129K 90 4 AIRCASTLE LTD CALL G0129K 95 4 AIRCASTLE LTD PUT G0176J 10 9 * ALLEGION PUB LTD CO ORD SHS G0176J 90 9 ALLEGION PUB LTD CO CALL G0176J 95 9 ALLEGION PUB LTD CO PUT G01767 10 5 * ALKERMES PLC SHS G01767 90 5 ALKERMES PLC CALL G01767 95 5 ALKERMES PLC PUT G02602 10 3 * AMDOCS LTD SHS G02602 90 3 AMDOCS LTD CALL G02602 95 3 AMDOCS LTD PUT G0335L 10 2 * AMIRA NATURE FOODS LTD SHS G0335L 90 2 AMIRA NATURE FOODS LTD CALL G0335L 95 2 AMIRA NATURE FOODS LTD PUT G037AX 10 1 * AMBARELLA INC SHS G037AX 90 1 AMBARELLA INC CALL G037AX 95 1 AMBARELLA INC PUT G0404E 10 4 AOXIN TIANLI GROUP INC USD COMMON SHS G0408V 10 2 * AON PLC SHS CL A G0408V 90 2 AON PLC CALL G0408V 95 2 AON PLC PUT G0450A 10 5 * ARCH CAP GROUP LTD ORD G0450A 90 5 ARCH CAP GROUP LTD CALL Run Date: 1/2/2015 ** List of Section 13F Securities ** Page 2 Run Time: 10:15 Year: 2014 Qtr: 4 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G0450A 95 5 ARCH CAP GROUP LTD PUT G0457F 10 7 * ARCOS DORADOS HOLDINGS INC SHS CLASS -A - G0457F 90 7 ARCOS DORADOS HOLDINGS INC CALL G0457F 95 7 ARCOS DORADOS HOLDINGS INC PUT G0464B 10 7 * ARGO GROUP INTL HLDGS LTD COM G0464B 90 7 ARGO GROUP INTL HLDGS LTD CALL G0464B 95 7 ARGO GROUP INTL HLDGS LTD PUT G0471F 10 9 * APCO OIL & GAS INTERNATIONAL SHS G0471F 90 9 APCO OIL & GAS INTERNATIONAL CALL G0471F 95 9 APCO OIL & GAS INTERNATIONAL PUT G0535E 10 6 ASIA PACIFIC WIRE & CABLE CO ORD G05384 10 5 * ASPEN INSURANCE HOLDINGS LTD SHS G05384 90 5 ASPEN INSURANCE HOLDINGS LTD CALL G05384 95 5 ASPEN INSURANCE HOLDINGS LTD PUT G0585R 10 6 * ASSURED GUARANTY LTD COM G0585R 90 6 ASSURED GUARANTY LTD CALL G0585R 95 6 ASSURED GUARANTY LTD PUT G06207 11 5 ATLAS FINANCIAL HOLDINGS INC SHS NEW G0692U 10 9 * AXIS CAPITAL HOLDINGS LTD SHS G0692U 90 9 AXIS CAPITAL HOLDINGS LTD CALL G0692U 95 9 AXIS CAPITAL HOLDINGS LTD PUT G07021 10 1 * CHC GROUP LTD SHS G07021 90 1 CHC GROUP LTD CALL G07021 95 1 CHC GROUP LTD PUT G0750C 10 8 * AXALTA COATING SYS LTD COM ADDED G0750C 90 8 AXALTA COATING SYS LTD CALL ADDED G0750C 95 8 AXALTA COATING SYS LTD PUT ADDED G10082 14 0 * ENERGY XXI LTD USD UNRS SHS G10082 90 0 ENERGY XXI LTD CALL G10082 95 0 ENERGY XXI LTD PUT G1151C 10 1 * ACCENTURE PLC IRELAND SHS CLASS A G1151C 90 1 ACCENTURE PLC IRELAND CALL G1151C 95 1 ACCENTURE PLC IRELAND PUT G1154H 10 7 * BELMOND LTD CL A Run Date: 1/2/2015 ** List of Section 13F Securities ** Page 3 Run Time: 10:15 Year: 2014 Qtr: 4 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G1154H 90 7 BELMOND LTD CALL G1154H 95 7 BELMOND LTD PUT G1190F 10 7 BLUE CAP REINS HLDGS LTD COM G16249 10 7 * BROOKFIELD PPTY PARTNERS L P UNIT LTD PARTN G16249 90 7 BROOKFIELD PPTY PARTNERS L P CALL G16249 95 7 BROOKFIELD PPTY PARTNERS L P PUT G16252 10 1 * BROOKFIELD INFRAST PARTNERS LP INT UNIT G16252 90 1 BROOKFIELD INFRAST PARTNERS CALL G16252 95 1 BROOKFIELD INFRAST PARTNERS PUT G16258 10 8 * BROOKFIELD RENEWABLE ENRGY P PARTNERSHIP UNIT G16258 90 8 BROOKFIELD RENEWABLE ENRGY P CALL G16258 95 8 BROOKFIELD RENEWABLE ENRGY P PUT G16962 10 5 * BUNGE LIMITED COM G16962 90 5 BUNGE LIMITED CALL G16962 95 5 BUNGE LIMITED PUT G20045 20 2 * CENTRAL EUROPEAN MEDIA ENTRP CL A NEW G20045 90 2 CENTRAL EUROPEAN MEDIA ENTRP CALL G20045 95 2 CENTRAL EUROPEAN MEDIA ENTRP PUT G2029P 10 0 C B PHARMA ACQUISITION CORP UNIT 99/99/9999 ADDED G21082 10 5 * CHINA YUCHAI INTL LTD COM G21082 90 5 CHINA YUCHAI INTL LTD CALL G21082 95 5 CHINA YUCHAI INTL LTD PUT G2110R 11 4 * CHIPMOS TECH BERMUDA LTD SHS G2110R 90 4 CHIPMOS TECH BERMUDA LTD CALL G2110R 95 4 CHIPMOS TECH BERMUDA LTD PUT G2110U 10 9 CHINA NATURAL RESOURCES INC COM G21101 10 3 * CHINA GERUI ADV MAT GR LTD SHS DELETED G21101 90 3 CHINA GERUI ADV MAT GR LTD CALL DELETED G21101 95 3 CHINA GERUI ADV MAT GR LTD PUT DELETED G21101 13 7 * CHINA GERUI ADV MAT GR LTD USD NEW ORD SHS ADDED G21101 90 7 CHINA GERUI ADV MAT GR LTD CALL ADDED G21101 95 7 CHINA GERUI ADV MAT GR LTD PUT ADDED G21107 10 0 CHINA CORD BLOOD CORP SHS G2113X 10 0 CHINA CERAMICS CO LTD SHS Run Date: 1/2/2015 ** List of Section 13F Securities ** Page 4 Run Time: 10:15 Year: 2014 Qtr: 4 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G21174 10 0 * CHINA INFORMATION TECHNOLOGY COM G21174 90 0 CHINA INFORMATION TECHNOLOGY CALL G21174 95 0 CHINA INFORMATION TECHNOLOGY PUT G21490 11 8 CIS ACQUISITION LTD *W EXP 12/18/201 G21490 20 9 CIS ACQUISITION LTD SHS SER A DELETED G21490 50 6 CIS ACQUISITION LTD UNIT 99/99/9999 DELETED G2266G 10 2 COLLABRIUM JAPAN ACQUISITN C SHS G2266G 11 0 COLLABRIUM JAPAN ACQUISITN C *W EXP 04/01/201 G2266G 12 8 COLLABRIUM JAPAN ACQUISITN C UNIT 99/99/9999 G23773 10 7 * CONSOLIDATED WATER CO INC ORD G23773 90 7 CONSOLIDATED WATER CO INC CALL G23773 95 7 CONSOLIDATED WATER CO INC PUT G2519Y 10 8 * CREDICORP LTD COM G2519Y 90 8 CREDICORP LTD CALL G2519Y 95 8 CREDICORP LTD PUT G25343 10 7 * COSAN LTD SHS A G25343 90 7 COSAN LTD CALL G25343 95 7 COSAN LTD PUT G2554F 11 3 * COVIDIEN PLC SHS G2554F 90 3 COVIDIEN PLC CALL G2554F 95 3 COVIDIEN PLC PUT G25861 AA 6 CTRIP COM INTERNATIONAL LTD DEBT 0.500% 9/1 G25861 AB 4 CTRIP COM INTERNATIONAL LTD DEBT 1.250%10/1 DELETED G2615J 10 4 DT ASIA INVTS LTD SHS ADDED G2615J 11 2 DT ASIA INVTS LTD RIGHT 03/30/2016 ADDED G2615J 12 0 DT ASIA INVTS LTD UNIT 99/99/9999T ADDED G2615J 13 8 DT ASIA INVTS LTD *W EXP 03/29/202 ADDED G27010 10 0 DEHAIER MEDICAL SYSTEMS LIMI SHS G27823 10 6 * DELPHI AUTOMOTIVE PLC SHS G27823 90 6 DELPHI AUTOMOTIVE PLC CALL G27823 95 6 DELPHI AUTOMOTIVE PLC PUT G29183 10 3 * EATON CORP PLC SHS G29183 90 3 EATON CORP PLC CALL G29183 95 3 EATON CORP PLC PUT Run Date: 1/2/2015 ** List of Section 13F Securities ** Page 5 Run Time: 10:15 Year: 2014 Qtr: 4 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G29438 10 1 E FUTURE INFORMATION TECH IN SHS G30397 10 6 * ENDURANCE SPECIALTY HLDGS LT SHS G30397 90 6 ENDURANCE SPECIALTY HLDGS LT CALL G30397 95 6 ENDURANCE SPECIALTY HLDGS LT PUT G30401 10 6 * ENDO INTL PLC SHS G30401 90 6 ENDO INTL PLC CALL G30401 95 6 ENDO INTL PLC PUT G3075P 10 1 ENSTAR GROUP LIMITED SHS G3156P 10 3 * ASA GOLD AND PRECIOUS MTLS L SHS G3156P 90 3 ASA GOLD AND PRECIOUS MTLS L CALL G3156P 95 3 ASA GOLD AND PRECIOUS MTLS L PUT G3157S 10 6 * ENSCO PLC SHS CLASS A G3157S 90 6 ENSCO PLC CALL G3157S 95 6 ENSCO PLC PUT G3163G 10 4 CHINA METRO-RURAL HLDGS LTD SHS G3198U 10 2 * ESSENT GROUP LTD COM G3198U 90 2 ESSENT GROUP LTD CALL G3198U 95 2 ESSENT GROUP LTD PUT G32030 12 7 EURO TECH HOLDINGS
Load more

Recommended publications
  • Say on Pay Results (As of September 5)
    THIS REPORT CAN BE ACCESSED AT HTTP://WWW.SEMLERBROSSY.COM/SAYONPAY NOTE: THIS WILL BE OUR FINAL SAY ON PAY UPDATE FOR 2012. WE WILL ISSUE A FULL REPORT PROVIDING RESULTS FOR THE ENTIRE 2012 PROXY SEASON IN JANUARY 2013. PLEASE CONTINUE TO VISIT OUR SAY ON PAY BLOG FOR UPDATES. SAY ON PAY RESULTS 2012 RUSSELL 3000 SEPTEMBER 5 2012 SAY ON PAY RESULTS: RUSSELL 3000 SHAREHOLDER VOTING SUMMARY OF FINDINGS 2012 Vote Results (n=2,025) 2 The majority of companies continue to pass Say on Pay in 2012 with substantial shareholder support: — 1,466 companies (72%) passed with over 90% support — 381 companies (19%) passed with between 70% and 90% support — 125 companies (6%) passed with between 50% and 70% support — 53 companies (2.6%) in the Russell 3000 have failed Vote of the Week McKesson received a vote of 62%, a decline of 8% from 2011, amidst criticism from shareholders and 3 their advisors over high relative CEO pay and retirement benefits Vote Results by Industry Health Care companies have received proportionally less support than other industries, while 4 Consumer Staple and Financial companies have received the most support Vote Results and Market Value 5 There does not appear to be a strong correlation between a company’s market value and Say on Pay vote result How Vote Results Changed in 2012 6 Companies below 70% in 2011 have generally received increased vote support in 2012: — 26 of 30 companies that failed in 2011 have passed in 2012 — Companies between 50‐70% in 2011 have improved by an average of 13% in 2012 Vote results for companies
    [Show full text]
  • Fidelity® Total Market Index Fund
    Quarterly Holdings Report for Fidelity® Total Market Index Fund May 31, 2021 STI-QTLY-0721 1.816022.116 Schedule of Investments May 31, 2021 (Unaudited) Showing Percentage of Net Assets Common Stocks – 99.3% Shares Value Shares Value COMMUNICATION SERVICES – 10.1% World Wrestling Entertainment, Inc. Class A (b) 76,178 $ 4,253,780 Diversified Telecommunication Services – 1.1% Zynga, Inc. (a) 1,573,367 17,055,298 Alaska Communication Systems Group, Inc. 95,774 $ 317,970 1,211,987,366 Anterix, Inc. (a) (b) 16,962 838,941 Interactive Media & Services – 5.6% AT&T, Inc. 11,060,871 325,521,434 Alphabet, Inc.: ATN International, Inc. 17,036 805,292 Class A (a) 466,301 1,099,001,512 Bandwidth, Inc. (a) (b) 34,033 4,025,764 Class C (a) 446,972 1,077,899,796 Cincinnati Bell, Inc. (a) 84,225 1,297,065 ANGI Homeservices, Inc. Class A (a) 120,975 1,715,426 Cogent Communications Group, Inc. (b) 66,520 5,028,912 Autoweb, Inc. (a) (b) 6,653 19,028 Consolidated Communications Holdings, Inc. (a) 110,609 1,035,300 Bumble, Inc. 77,109 3,679,641 Globalstar, Inc. (a) (b) 1,067,098 1,707,357 CarGurus, Inc. Class A (a) 136,717 3,858,154 IDT Corp. Class B (a) (b) 31,682 914,343 Cars.com, Inc. (a) 110,752 1,618,087 Iridium Communications, Inc. (a) 186,035 7,108,397 DHI Group, Inc. (a) (b) 99,689 319,005 Liberty Global PLC: Eventbrite, Inc. (a) 114,588 2,326,136 Class A (a) 196,087 5,355,136 EverQuote, Inc.
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]
  • The Weekly Shot Biotech Issue a Weekly Summary of Healthcare Industry Valuation and Near-Term Catalysts June 17, 2010
    Small Cap The Weekly Shot Biotech Issue June 17, 2010 A weekly summary of healthcare industry valuation and near-term catalysts The Weekly Shot: Overview and Comment - Small Cap Biotechnology Next week's sector highlights include LGND’s Thursday analyst event at the Eventi - Pharmaceuticals and Large Cap Biotech Hotel in NYC. The company on 6/15 announced updated 2010 revenue guidance of approx $25M, op ex of approx $30M, and expects to finish the year with $30M - Generics and Specialty Pharmaceuticals in cash (vs approx $43M as of 1Q10). Management will likely focus on partner GSK’s progress with add’l trials of Promacta (for ITP), which could potentially expand the drug’s label to Hep C, AML, and MDS (LGND receives <10% royalty from GSK). Investors should focus on pipeline plans following LGND’s opportunistic 2008/09 M&A activity. Key pipeline programs include LGD-4033 (ph.I, SARM candidate from PCOP) and RG7348, partnered with Roche (ph.I, Hep C candidate from MBRX). We do not expect major data announcements at the event. FDA’s Pediatric Drugs Advisory Committee will meet Monday to discuss pediatric safety reviews of multiple approved drugs, including Kogenate, Casodex, Apidra, NovoLog, Arimidex, Desmopressin, Prevacid, Nexium, Aciphex, Priolex, OraVerse, Zemuron, and Suprane . While important from a public safety perspective, we do not anticipate regulatory activity to be announced. Brian Lian, Ph.D. Small caps biotechs rebounded mid-week as elevated volatility continued across 212.500.6646 [email protected] the broader market. Investors are struggling to balance economic data supporting a modest recovery against concerns on EU debt loads, financial reform legislation, and aggressive govt rhetoric on BP’s oil spill.
    [Show full text]
  • Immunotherapy Opportunity Emerges for Alzheimer Disease
    RESEARCH HIGHLIGHTS Nature Reviews Drug Discovery | Published online 26 Feb 2016; doi:10.1038/nrd.2016.38 NEURODEGENERATIVE DISEASE Immunotherapy opportunity emerges for Alzheimer disease Although an overactive immune trafficking to the brain, which 1-month interval between sessions, system was thought to be involved promoted clearance of Aβ and reached performance levels com- in the development of Alzheimer improved cognitive function in parable to control mice. Conversely, disease (AD), recent studies have a mouse model of AD. As PD1 when mice that had received a single indicated that boosting the immune checkpoint blockade has been shown session of PD1 blockade were response in the brain might ameliorate to stimulate an IFNγ-dependent examined 2 months later there was disease. Now, writing in Nature immune response in cancer only a marginal improvement in Medicine, Schwartz and colleagues immuno therapy, Schwartz and memory, suggesting that repeated report that immune-checkpoint colleagues set out to explore the treatment sessions are needed to blockade directed against the therapeutic potential of PD1 maintain the beneficial effects. programmed cell death protein 1 blockade in AD. Examination of the brains of (PD1) pathway promotes cerebral To do this, they treated the 5XFAD mice after treatment with amyloid-β (Aβ) clearance and 5 familial AD mutations (5XFAD) the PD1-specific antibody revealed a improves cognitive function in mouse model of AD at 10 months reduction in the cerebral Aβ-plaque mouse models of AD. old (an age at which cerebral pathology load in the hippocampus and in the In a previous study, the authors is advanced) with 2 intraperitoneal cerebral cortex (the main anatomical demonstrated that inhibition of injections of a PD1-specific antibody regions with robust Aβ-plaque forkhead box P3-positive regulatory at 3-day intervals.
    [Show full text]
  • Fourth-Quarter Biotech Job Picture
    CAREERS AND RECRUITMENT Fourth-quarter biotech job picture Michael Francisco he number of biotech sector jobs advertised in the fourth quarter of Finally, the Jackson Laboratory (Bar Harbor, ME, USA) announced a T2011 was down slightly compared with the third quarter, whereas tentative plan to create a center for personalized medicine and genomics pharma sector hiring numbers were similar (Nat. Biotechnol. 29, 1053, in Connecticut. The Jackson Laboratory for Genomic Medicine, to be 2011) as seen in three representative job databases tracked by Nature located near the University of Connecticut Health Center in Farmington, Biotechnology (Tables 1 and 2). would have a budget of about $1.1 billion, with The Jackson Laboratory China continues to attract new investment, as Quintiles Transnational providing $809 million through federal research grants and philanthropy. (Research Triangle Park, NC, USA) launched Kun Tuo, a Beijing-based The center would employ 300 people within the first 10 years and 600 contract research organization providing clinical trial management, employees within 20 years. regulatory submission preparation, biostatistics and data management Fourth-quarter downsizings within the life science industry are shown services to Chinese biotech and pharma companies. Quintiles plans to in Table 3. add 300 employees in China this year. The US Northeast was another hotbed of job growth, with 11 New York–based medical centers coming together with Illumina (San Diego) Table 2 Advertised job openings at the ten largest pharma companies and Roche (Basel) to create the New York Genome Center, a nonprofit Number of advertised openingsb a genomics collaboration that will include the creation of a research facil- Company Number of employees Monster Biospace Naturejobs Johnson & Johnson 119,200 487 12 0 ity in Manhattan in the spring.
    [Show full text]
  • The Securities and Exchange Commission Has Not Necessarily Reviewed the Information in This Filing and Has Not Determined If It Is Accurate and Complete
    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0006 Washington, D.C. 20549 Oct 31, FORM 13F Expires: 2018 FORM 13F COVER PAGE Estimated average burden hours per 23.8 response: Report for the Calendar Year or Quarter Ended: 09-30-2020 Check here if Amendment Amendment Number: This Amendment (Check only one.): is a restatement. adds new holdings entries. Institutional Investment Manager Filing this Report: Name: The PNC Financial Services Group, Inc. Address: The Tower at PNC Plaza 300 Fifth Avenue Pittsburgh, PA 15222-2401 Form 13F File Number: 028-01235 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Gregory H. Kozich Title: Senior Vice President & Controller Phone: (888) 762-2265 Signature, Place, and Date of Signing: /s/ Gregory H. Kozich Pittsburgh, PA 11-06-2020 [Signature] [City, State] [Date] Report Type (Check only one.): X 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) 13F COMBINATION REPORT.
    [Show full text]
  • The Securities and Exchange Commission Has Not Necessarily Reviewed the Information in This Filing and Has Not Determined If It Is Accurate and Complete
    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0006 Washington, D.C. 20549 Oct 31, FORM 13F Expires: 2018 FORM 13F COVER PAGE Estimated average burden hours per 23.8 response: Report for the Calendar Year or Quarter Ended: 12-31-2017 Check here if Amendment Amendment Number: This Amendment (Check only one.): is a restatement. adds new holdings entries. Institutional Investment Manager Filing this Report: Name: US BANCORP \DE\ Address: U.S. BANCORP 800 NICOLLET MALL MINNEAPOLIS, MN 55402-7020 Form 13F File 028-00551 Number: The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Julie von Arx Title: Assistant Vice President Phone: 651-605-8656 Signature, Place, and Date of Signing: Julie von Arx Minneapolis, MN 02-01-2018 [Signature] [City, State] [Date] Report Type (Check only one.): X 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) 13F COMBINATION REPORT.
    [Show full text]
  • 8Th Annual BIO Investor Forum
    Monday Conrad Duke of Windsor Park South Basildon East Foyer Jade/Astor February 11, 2013 4th Floor 3rd Floor 7:00 – 7:55am Networking Breakfast: Grand Ballroom 8:00 – 8:45am Fireside Chat with Robert Hugin, Chairman and CEO, Celgene Corporation (Astor) Oxygen Proteon Therapeutics 9:00 – 9:25am Innovus Pharma Galena BioPharma GTx Biotherapeutics Tobira Therapeutics Show Me the Money: Reimbursement in an ACA World Transition Regado Biosciences 9:30 – 9:55am Verastem Advaxis ChemoCentryx (Jade) Therapeutics ALS TDI (PAG) CoLucid Pharmaceuticals ImmunoCellular 10:00 – 10:25am Advanced Cell Technology TBD Rigel Pharmaceuticals Actinium Pharmaceuticals Therapeutics Onconova Therapeutics Furiex 10:30 – 10:55am ReNeuron GENFIT NPS Pharmaceuticals Oncology: uniQure Pharmaceuticals Panning for Gold—Prospecting Fate Therapeutics Lexicon the Pancreatic Pipeline 11:00 – 11:25am Palatin Technologies CEL-SCI Corporation Repros Therapeutics Zafgen Pharmaceuticals (Jade) NovaBay Provectus LL Society (PAG) Tonix 11:30 – 11:55am Agenus Pharmaceuticals Pharmaceuticals Five Prime Therapeutics Pharmaceuticals 12:00 – 12:55pm Opening Plenary Session: Word on the Street – Buy-Side View for 2013 (Jade) – Box Lunch Catabasis Pharmaceuticals Fireside Chat with John Lechleiter, 1:00 – 1:25pm Anteo Diagnostics Atossa Genetics Targacept Synergy Pharmaceuticals Promedior Chairman, President & CEO, Eli Lilly KineMed (Astor; 1:00-1:45pm) 1:30 – 1:55pm ProMetic Life Sciences CytRx Corporation Biotie Therapies Cytokinetics TVAX Biomedical Good Start Genetics 2:00 – 2:25pm
    [Show full text]
  • Cleveland Biolabs
    Controlling Cell Death To Protect Human Life iJ Cleveland BioLabs 2011 Annual Report company with focus for is being developed ue U.S Food Drug Administrations nal Efficac U-LC agent and an oncologic supportive care the FDAs traditional drug approval pathway We anticipate that CBLB5O2 upon nsure as radiation countermeasure will be sold to the U.S government for the national stockpile and other defense-related purposes friendly foreign governments and the nuclear energy industry and upon licensure as an anti-cancer agent will be sold to the public through traditional channels Since our inception we have pursued the research development and commercialization of products that have the potential to evidence direct anti-cancer activity prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology candidates in that patients Presently we have nine product our pipeline are being developed and Inc directly by us and our majority-owned subsidiaries Incuron LLC Panacela Labs Mission Statement CBLIs mission is to develop and commercialize innovative drugs to treat cancer and protect scientific healthy tissues from radiation chemotherapy or ischemic conditions using revolutionary concepts developed at CBLI and in collaboration with distinguished academic partners Talented scientists experienced drug development executives and innovative entrepreneurs comprise balanced CBLI team united by common goals to make difference in the lives of untreatable patients and to cure people suffering from previously
    [Show full text]
  • Sponsors.Pdf
    Customer Name OSP0001 ABB Automation Inc. OSP0002 ABT Associates Inc. OSP0003 Acromed Corporation OSP0004 ADRC Technologies Inc. OSP0005 Aerogen Inc. OSP0006 Aeropharm Inc. OSP0007 Air Products Inc. OSP0008 Algaeventure Systems OSP0009 AmTrust Bank OSP0010 Analex Corporation OSP0011 Applied Pavement Technology Inc. OSP0012 Arcus Technology OSP0013 Babcock & Wilcox OSP0014 Booz Allen Hamilton OSP0015 BP America OSP0016 Bramhall Engineering & Surveying Co Inc. OSP0017 Caddscan Engineering OSP0018 CalAsia Pharmaceuticals OSP0019 Cedar Fair LLP OSP0020 Centerior Energy OSP0021 Central Parc LLC OSP0022 Cleveland Advanced Manufacturing Program OSP0023 Cleveland BioLabs Inc. OSP0024 Cleveland Medical Devices Inc. OSP0025 Constella Group OSP0026 Controlsoft Inc. OSP0027 Crain's Cleveland Business OSP0028 Creative Department LLC OSP0029 Curragh Chemistries Inc. OSP0030 Cytodyne Technologies OSP0031 DataQ Instruments Inc. OSP0032 Deformation Control Technology Inc. OSP0033 Deloitte Consulting OSP0034 Dominion East Ohio Gas OSP0035 Donald McTigue Esq Attorney-at-Law OSP0036 Dr. Mitchell Wax OSP0037 Dr. Sarah Staneff OSP0038 Dr. Theodore Castele OSP0039 Evergreen Cooperatives of Cleveland Ohio OSP0040 Federal Mogul Corporation OSP0041 Ferro Corporation OSP0042 Flow Parametrics LLC OSP0043 Ford Motor Company OSP0044 Forest City Enterprises OSP0045 Gebauer Company OSP0046 Gemstar Group OSP0047 General Electric OSP0048 General Electric Consumer&Industrial OSP0049 General Electric Lighting OSP0050 General Motors Corporation OSP0051 General Motors North American Operations OSP0052 General Motors-CWR Division OSP0053 Group Services Inc. OSP0054 Hemisphere Corporation OSP0055 Hydraulic Press Brick Company OSP0056 ICF Incorporated OSP0057 Industrial Advisors Bureau Inc. OSP0058 Industry Week Magazine OSP0059 Innovative Developments OSP0060 I-Open Ventures LLC OSP0061 JEK Analytics OSP0062 Jones Day Reavis and Pogue OSP0063 JumpStart Inc OSP0064 Keip Government Solutions Consulting OSP0065 Keithley Instruments Inc.
    [Show full text]
  • Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All
    2013 MEDICINES IN DEVELOPMENT REPORT Rare Diseases A Report on Orphan Drugs in the Pipeline PRESENTED BY AMERICA’s biopharmACEUTICAL RESEARCH COMPANIES More Than 450 Medicines in Development for Rare Diseases Rare diseases, when taken together, are A major area of this research targets Orphan Drugs in Development* not that rare at all. In fact, according to rare cancers, accounting for more than Application the National Institutes of Health (NIH), one-third of all rare disease medicines in Submitted 30 million Americans have one of the development. Other top research areas Phase III nearly 7,000 diseases that are officially include genetic disorders, neurologi- Phase II deemed “rare” because alone they each cal conditions, infectious diseases and Phase I affect fewer than 200,000 people in autoimmune disorders. the United States. Sometimes, only Despite some recent victories, research a few hundred patients are known to 105 into treatments for rare diseases is a have a particular rare disease. daunting quest. This ongoing innovation Simply receiving a diagnosis of a rare and the hundreds of new medicines in disease often becomes a frustrating development now offer hope that physi- 85 quest, since many doctors may have nev- cians will have new treatment options er before heard of or seen the disease. for patients confronting a rare disease. This is, however, a time of great progress and hope. Biopharmaceutical 65 Contents research is entering an exciting new era Innovative Orphan Drugs with a growing understanding of the in the Pipeline ......................................... 2 human genome. Scientific advances have given researchers new tools to Orphan Drug Approvals ...........................4 explore rare diseases, which are often Challenges in Clinical Trials ......................6 more complex than common diseases.
    [Show full text]